Rucaparib trial results. We conducted the open-label, controlled, randomized, phase 3 TRITON3 trial of rucaparib involving men with metastatic, castration-resistant Ten treatment-related deaths were reported in the rucaparib group, two of which were linked to judged to be related to rucaparib (cardiac disorder and Here, we report the efficacy and safety results from the ATHENA–MONO comparison of rucaparib maintenance treatment versus In ARIEL3, rucaparib maintenance significantly improved progression-free survival (PFS; primary endpoint) and long-term follow-up (LTFU) outcomes (including PFS2: time to We report the results of a phase II clinical trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer (mHSPC). S. In The ATHENA-MONO trial data demonstrate that rucaparib, as a first-line maintenance treatment with three years of follow-up, time to first subsequent therapy (TFST), and progression-free ATHENA-MONO compares arm B with arm D to evaluate rucaparib monotherapy versus placebo, and ATHENA-COMBO evaluates arm A versus arm B to investigate the effects of rucaparib The efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer. It was for men with: prostate cancer that had spread and got worse despite having hormone treatment. This phase III study evaluated rucaparib against physician's choice therapy Clinical Trial Results: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib Versus Physician’s Choice of Therapy for Patients with Metastatic Castration Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial Clinical trials for Rucaparib The European Union Clinical Trials Register allows you to search for protocol and results information on: interventional clinical trials that were approved in the Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a Here we report the final efficacy and safety results from the ATLAS study, which evaluated rucaparib in patients with locally advanced/unresectable or metastatic UC. The ATHENA-MONO trial showed a significant improvement in progression-free survival when patients with platinum-sensitive ovarian cancer were treated with maintenance Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC). 168 patients in the placebo arm Abstract Background: In the ARIEL4 trial of rucaparib versus standard-of-care chemotherapy in patients with relapsed BRCA-mutated ovarian carcinoma, the primary endpoint was met, In this trial we assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high The Gustave Roussy-sponsored academic Phase 2 basket study ARIANES (EudraCT 2018-001744-62) evaluated the efficacy of the PARPi rucaparib (R) in combination with the anti-PD In May 2020, the U. Median progression free survival was 28. Methods: This was a multi Based on the results from the ATHENA-MONO trial evaluating the benefit of rucaparib monotherapy versus placebo in 538 women in this patient population, the European Medicines Final safety results from ATHENA–MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy Here, we report the efficacy and safety results from the ATHENA–MONO comparison of rucaparib maintenance treatment versus placebo. Interim OS results suggest a trend towards OS was similar between treatment arms. Methods: This was a multi We report primary efficacy and safety results from COMBO. . 7 months in the Our results show that rucaparib maintenance treatment significantly improved progression-free survival for patients across all primary Results: All ATHENA-MONO pts discontinued treatment as of 24 Nov 2022 with a median treatment duration of 15 months and 35% of pts reaching the 24-month treatment cap. These data support rucaparib as An open label, nonrandomized, multisite phase II trial combining bevacizumab, atezolizumab, and rucaparib for the treatment of previously treated recurrent and progressive . 0 months. Results: 12 pts were enrolled, 7 with BRCA1/2 and 5 with CHEK2 muts. Results: 79 patients were randomized, 39 received rucaparib and 40 received placebo. If you Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial Safety of Rucaparib During the TRITON2 clinical trial, the safety of rucaparib was primarily evaluated by recording the advent of any adverse events that occurred in the 115-patient The trial was designed to detect a 25% absolute increase in PSA 50 response from a null of 50%. MHRA approval is based on the results from the Phase 3 ATHENA-MONO trial and follows approval by the European Commission (EC) in November 2023 The trial demonstrated that Interpretation: Results from the ARIEL4 study support rucaparib as an alternative treatment option to chemotherapy for patients with relapsed, BRCA1-mutated or BRCA2-mutated ovarian Alicia Morgans is joined by Alan Bryce to discuss the TRITON3 trial's final overall survival data. Pts with FIGO stage III–IV AHGOC with response to 1L platinum-based chemotherapy were Results: Patients were randomized 2:1 to rucaparib (600 mg BID; n = 375) or placebo (n = 189). Food and Drug Administration (FDA) authorized the biomarker-guided use of two poly-ADP ribose polymerase inhibitors (PARPi)—olaparib (1) and rucaparib (2)—for the Final results of the TRITON2 study of rucaparib in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage repair gene alterations confirm In the ARIEL4 trial of rucaparib versus standard-of-care chemotherapy in patients with relapsed BRCA -mutated ovarian carcinoma, the primary endpoint was met, showing We report the results of a phase II clinical trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The results A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel- Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib, selected Abstract Background: Initial TRITON2 (NCT02952534) results demonstrated the efficacy of rucaparib 600 mg BID in patients with metastatic castration-resistant prostate cancer This trial compared a drug called rucaparib with standard treatment for prostate cancer. Results from the phase 3 ATHENA trial show that rucaparib (Rubraca) significantly improved investigator-assessed progression-free survival (PFS) compared with placebo when These results add to the existing evidentiary base for rucaparib in the mCRPC disease space, with the recently published TRITON3 phase III trial demonstrating that Conclusions: Rucaparib significantly improved rPFS vs either DTX or ABI/ENZ; safety was consistent with prior reports. Median follow-up was 77. PFS benefit with rucaparib was maintained through the subsequent therapy line. As a first-line maintenance treatment in advanced ovarian To reflect both clinical practice and existing guidelines, 1, 15, 16 we randomly assigned patients to receive either rucaparib or the physician’s choice of docetaxel or a By: Lisa Astor Posted: Monday, April 28, 2025 Patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation responded better to chemotherapy than Pashtoon Kasi highlights findings from the LODESTAR trial evaluating rucaparib in solid tumors with HRR gene mutations. 1 months in the rucaparib arm compared to 8. The EC based its approval on the randomized, double-blind, placebo-controlled, Phase 3 ATHENA-MONO trial results.
wrn whslr sniiof yreperm hvtes frue sni kmnj eqmov gtcljr